TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12200985

Group type: EXPERIMENTAL
Intervention: Low dose EPO (250 IU/kg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High dose EPO (400 IU/kg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (PRBC transfusions)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combined low and high dose EPO
Number of subjects: 93
Study: 10626189

Group type: EXPERIMENTAL
Intervention: Natural beta-IFN (6 MU/tiw for 6 months followed by 3 MU/tiw for 6 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61
Study: 8955543

Group type: EXPERIMENTAL
Intervention: High dietary restraint in 16-year-old girls under high anxiety conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dietary restraint in both age groups for forbidden foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dietary restraint in 16-year-old girls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permitted food consumption
Number of subjects: 0
Study: 2011422

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 536

Group type: COMPARATOR
Intervention: Myringotomy alone
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Amoxicillin alone
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Amoxicillin with myringotomy
Number of subjects: 536
Study: 7048248

Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30918967

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg twice daily during and 2 weeks after tuberculosis therapy, then 50 mg once daily for 52 weeks
Number of subjects: 113

Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg daily with 2 nucleoside reverse transcriptase inhibitors for 52 weeks
Number of subjects: 113
Study: 30573417

Group type: EXPERIMENTAL
Intervention: Improved infant and young child feeding (IYCF)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Standard of care (non-IYCF)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Improved water, sanitation, and hygiene (WASH)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Standard of care (non-WASH)
Number of subjects: 668
Study: 29066437

Group type: EXPERIMENTAL
Intervention: Vitamin D 4000 IU (100 μg) daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Vitamin D 2000 IU (50 μg) daily
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Echocardiographic measures
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Plasma N-terminal prohormone of brain natriuretic peptide
Number of subjects: 305
Study: 26087472

Group type: EXPERIMENTAL
Intervention: SPARC (Sheffield Profile for Assessment and Referral for Care) at baseline, n = 87
Number of subjects: 182

Group type: COMPARATOR
Intervention: Waiting-list control (no SPARC at baseline), n = 95
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: SPARC and Waiting-list control
Number of subjects: 182
Study: 24740208

Group type: EXPERIMENTAL
Intervention: Dairy fat intake (measured by biomarkers trans‐16:1n‐7, 15:0, and 17:0)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dairy fat intake (specifically phospholipid trans‐16:1n‐7)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (BMI- and age-matched)
Number of subjects: 32
Study: 22855557

Group type: EXPERIMENTAL
Intervention: Off β-blockers (Off-BB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: On β-blockers (On-BB)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Off-BB
Number of subjects: 19

Group type: COMPARATOR
Intervention: On-BB
Number of subjects: 19
Study: 19395688

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 17393618

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no leukogenic drugs)
Number of subjects: 0
Study: 15733486

Group type: EXPERIMENTAL
Intervention: Laser treatment with indocyanine green solution (1 mg/ml) injected submucosally and diode laser (power 10 watts) applied to the surface from the esophagogastric junction to 5 cm above it.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group without any treatments.
Number of subjects: 42
Study: 11555762

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (n = 9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study: 9683388

Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUD)
Number of subjects: 6648

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 6648

Group type: COMPARATOR
Intervention: Menstruating women (general population)
Number of subjects: 6648

Group type: COMPARATOR
Intervention: Post-menopausal women
Number of subjects: 6648

Group type: COMPARATOR
Intervention: Dietary iron intake
Number of subjects: 6648

Group type: COMPARATOR
Intervention: Men
Number of subjects: 6648
Study: 8152576

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 90
Study: 3244540

Group type: EXPERIMENTAL
Intervention: Thymomodulin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29473481

Group type: EXPERIMENTAL
Intervention: Focal sensorimotor exercise training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Functional exercise training (control group)
Number of subjects: 52
Study: 28330497

Group type: EXPERIMENTAL
Intervention: Anti-IgE treatment (omalizumab) for 6 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26435229

Group type: EXPERIMENTAL
Intervention: Physical therapy administered to 25 patients
Number of subjects: 53

Group type: COMPARATOR
Intervention: No physical therapy administered to 28 patients
Number of subjects: 53
Study: 24331343

Group type: EXPERIMENTAL
Intervention: Combination of general and epidural anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study: 21149672

Group type: EXPERIMENTAL
Intervention: ATG+CSA
Number of subjects: 88

Group type: COMPARATOR
Intervention: BSC
Number of subjects: 88
Study: 18364043

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) treatment by mothers of febrile children, supported by local women group leaders; CQ was regularly supplied through a revolving fund from local health centres.
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1076
Study: 17074200

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no RF ablation)
Number of subjects: 20
Study: 12007953

Group type: EXPERIMENTAL
Intervention: EBRT (50.4 Gy/28 fractions) with concurrent continuous infusion of 5-FU (200 mg/m²/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No chemoradiation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: EBRT with concurrent continuous 5-FU infusion
Number of subjects: 31

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 31
Study: 10481772

Group type: EXPERIMENTAL
Intervention: Coumarin/Troxerutine (Venalot Depot)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8577007

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isonitrogenous control diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both diets (Glutamine-supplemented and Isonitrogenous control)
Number of subjects: 30
Study: 1684678

Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) 40-80 mg daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) combined with triampur
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) combined with propranolol (PP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ketanserin (KS) combined with prazosin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blocker propranolol (PP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diuretic triampur
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Alpha 1-adrenergic blocker prazosin
Number of subjects: 51
Study: 6122752

Group type: EXPERIMENTAL
Intervention: Combined beta‐blocker‐chlorthalidone treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Addition of a beta‐blocker
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorthalidone monotherapy
Number of subjects: 20
Study: 28699032

Group type: EXPERIMENTAL
Intervention: ME-CyA + prednisolone (PSL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: prednisolone (PSL) alone
Number of subjects: 21
Study: 27185680

Group type: EXPERIMENTAL
Intervention: Oral mask (OM) ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face mask (FM) ventilation
Number of subjects: 0
Study: 25664626

Group type: EXPERIMENTAL
Intervention: Participants in the NELSON lung cancer screening trial
Number of subjects: 15822

Group type: COMPARATOR
Intervention: Eligible nonresponders
Number of subjects: 15822
Study: 23190762

Group type: EXPERIMENTAL
Intervention: Preinfarction angina
Number of subjects: 430

Group type: COMPARATOR
Intervention: No preinfarction angina (Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Preinfarction angina (anterior STEMI)
Number of subjects: 430

Group type: COMPARATOR
Intervention: No preinfarction angina (anterior STEMI Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Preinfarction angina (non-anterior STEMI)
Number of subjects: 430

Group type: COMPARATOR
Intervention: No preinfarction angina (non-anterior STEMI Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Preinfarction angina (female gender)
Number of subjects: 430

Group type: COMPARATOR
Intervention: No preinfarction angina (female gender Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Preinfarction angina (male gender)
Number of subjects: 430

Group type: COMPARATOR
Intervention: No preinfarction angina (male gender Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Preinfarction angina (ischemia time ≤ 4h)
Number of subjects: 430

Group type: COMPARATOR
Intervention: No preinfarction angina (ischemia time ≤ 4h Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Preinfarction angina (ischemia time > 4h)
Number of subjects: 430

Group type: COMPARATOR
Intervention: No preinfarction angina (ischemia time > 4h Control)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Preinfarction angina (after correction for baseline characteristics)
Number of subjects: 430
Study: 21044933

Group type: EXPERIMENTAL
Intervention: Immunonutrition feed supplemented with glutamine, arginine, omega-3 fatty acids, tributyrin, vitamin C, E, B-carotene, and micronutrients (zinc, selenium, chromium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control feed (isonitrogenous, isocaloric)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunonutrition feed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control feed
Number of subjects: 0
Study: 18656600

Group type: EXPERIMENTAL
Intervention: Hemoclip
Number of subjects: 699

Group type: COMPARATOR
Intervention: Control
Number of subjects: 699
Study: 16498702

Group type: EXPERIMENTAL
Intervention: Reference Pricing (RP) for anti-hypertensive drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Public plan without RP
Number of subjects: 0
Study: 12894958

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 2208
Study: 11127163

Group type: EXPERIMENTAL
Intervention: Different surgical approaches for treating menorrhagia (not specified in detail)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 1
Study: 9374606

Group type: EXPERIMENTAL
Intervention: Counterfactual thinking and hindsight bias
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8507812

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study: 3830040

Group type: EXPERIMENTAL
Intervention: Peptide diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal low fat diet
Number of subjects: 9
Study: 31218477

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (50,000 IU weekly for 12 weeks, followed by 2000 IU daily for 40 weeks)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard-dose vitamin D3 (800 IU daily for 52 weeks)
Number of subjects: 93
Study: 29339097

Group type: EXPERIMENTAL
Intervention: Venetoclax plus intravenous decitabine 20 mg/m2 (days 1-5 of each 28-day cycle)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Venetoclax plus subcutaneous or intravenous azacitidine 75 mg/m2 (days 1-7 of each 28-day cycle)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Venetoclax plus decitabine with posaconazole (CYP3A inhibitor)
Number of subjects: 57
Study: 26705010

Group type: EXPERIMENTAL
Intervention: Nasal route
Number of subjects: 220

Group type: COMPARATOR
Intervention: Oral route
Number of subjects: 220
Study: 24824050

Group type: EXPERIMENTAL
Intervention: Enhanced HIV pre‐ and post‐test counseling, legal support, and access to support groups at baseline, six and ten weeks postpartum
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Standard HIV testing and counseling (HTC) and two postpartum attention control sessions
Number of subjects: 1480
Study: 22395837

Group type: EXPERIMENTAL
Intervention: Dopamine 3 µ/kg/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20856123

Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/day
Number of subjects: 515

Group type: COMPARATOR
Intervention: Fluoxetine 20-40 mg/day
Number of subjects: 515
Study: 18035433

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study: 16028252

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis with recombinant tissue plasminogen activator (rtPA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis with rtPA and GPIIb/IIIa receptor antagonist tirofiban
Number of subjects: 47

Group type: COMPARATOR
Intervention: No thrombolysis (nontreated patients)
Number of subjects: 47
Study: 12840617

Group type: EXPERIMENTAL
Intervention: Cold pressor test (intermittent immersion of the hand into ice water)
Number of subjects: 76
Study: 10794337

Group type: EXPERIMENTAL
Intervention: Predonated autologous whole blood
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Red cell salvage
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Reinfusion of shed mediastinal blood
Number of subjects: 713
Study: 8851073

Group type: EXPERIMENTAL
Intervention: 27 degrees C
Number of subjects: 83

Group type: COMPARATOR
Intervention: 21 degrees C
Number of subjects: 83
Study: 1289514

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg SR
Number of subjects: 1464

Group type: COMPARATOR
Intervention: Chlorthalidone 25 mg
Number of subjects: 1464
Study: 3890732

Group type: EXPERIMENTAL
Intervention: Single-dose tetracycline (2 g)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multi-dose tetracycline (500 mg four times per day for 10 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin (3 g)
Number of subjects: 62
Study: 31288480

Group type: EXPERIMENTAL
Intervention: Eating while working on a computer
Number of subjects: 43

Group type: COMPARATOR
Intervention: Eating quietly and at rest (control)
Number of subjects: 43
Study: 30025397

Group type: EXPERIMENTAL
Intervention: Bushen Formula (BSF) combined with enticavir (ETV) for 12 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo combined with enticavir (ETV) for 12 months
Number of subjects: 64
Study: 27720506

Group type: EXPERIMENTAL
Intervention: 0.2mg oral clonidine one hour before the operation in addition to standard anesthesia procedure
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard anesthesia procedure alone
Number of subjects: 52
Study: 25082565

Group type: EXPERIMENTAL
Intervention: Sequential erlotinib 150 mg/d (day 2-16) + docetaxel (75 mg/m² day 1)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² day 1) alone
Number of subjects: 147
Study: 21176556

Group type: EXPERIMENTAL
Intervention: Levornidazole
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ornidazole
Number of subjects: 143
Study: 15586364

Group type: EXPERIMENTAL
Intervention: Ablative therapy (APC or PDT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ablative therapy (APC)
Number of subjects: 29
Study: 12039395

Group type: EXPERIMENTAL
Intervention: Fidarestat (SNK-860; 1 mg daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Epalrestat (150 mg daily)
Number of subjects: 58
Study: 9577105

Group type: EXPERIMENTAL
Intervention: Fully programmed edgewise appliance (FPA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Partly programmed edgewise appliance (PPA)
Number of subjects: 61
Study: 8120703

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 5400

Group type: COMPARATOR
Intervention: Placebo or no drug
Number of subjects: 5400
Study: 3164762

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (2 to 3 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular diazepam (0.25 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11246935

Group type: EXPERIMENTAL
Intervention: Distant healing (anonymous, amulet, allowing for personal contact)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 119
Study: 30291994

Group type: EXPERIMENTAL
Intervention: Effective dose (Deff) with n = 0.5
Number of subjects: 203

Group type: COMPARATOR
Intervention: Mean lung dose (MLD) with n = 1
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 203
Study: 29573665

Group type: EXPERIMENTAL
Intervention: dHR+ (ER+/PgR+)
Number of subjects: 571

Group type: COMPARATOR
Intervention: sHR+ (ER+/PgR–)
Number of subjects: 571

Group type: COMPARATOR
Intervention: sHR+ (ER–/PgR+)
Number of subjects: 571
Study: 26967219

Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (NF: folate, alpha‐tocopherol, B12, S‐adenosyl methionine, N‐acetyl cysteine, acetyl‐L‐carnitine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nutraceutical formulation (NF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 24
Study: 24639042

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 36
Study: 22852832

Group type: EXPERIMENTAL
Intervention: Extended Care (multi-component smoking cessation intervention including up to three months of free FDA-approved smoking cessation medication and five proactive computerized telephone calls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care (recommendation for a smoking cessation medication and information about community resources)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended Care
Number of subjects: 0
Study: 19383060

Group type: EXPERIMENTAL
Intervention: Abnormal glycaemia (including diabetes, impaired fasting glucose, post-stroke dysglycaemia)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Dyslipidaemia
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combination of abnormal glycaemia, hypertension, and dyslipidaemia
Number of subjects: 224
Study: 17274708

Group type: EXPERIMENTAL
Intervention: Test SEI with nanometer-sized calcium phosphate treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control SEI with dual acid-etched surface without treatment
Number of subjects: 15
Study: 15159491

Group type: COMPARATOR
Intervention: Minocycline 200 mg/day for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Minocycline up to 400 mg/day for 8 months (mean tolerated dose 387 mg/day)
Number of subjects: 42
Study: 12005090

Group type: EXPERIMENTAL
Intervention: Malaria chemoprophylaxis during the first year of life
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Children with malaria episodes
Number of subjects: 675

Group type: COMPARATOR
Intervention: Children without malaria episodes
Number of subjects: 675
Study: 9828914

Group type: EXPERIMENTAL
Intervention: PD-GHRH test with hydrocortisone (HC) 80 mg/day for 1 day
Number of subjects: 24

Group type: COMPARATOR
Intervention: PD-GHRH test with no glucocorticoid pretreatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: PD-GHRH test with conventional HC therapy (30 mg/day for 1 and 3 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PD-GHRH test with HC (80 mg/day for 1 day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: PD-GHRH test with short-term hypocortisolism
Number of subjects: 24
Study: 8055122

Group type: EXPERIMENTAL
Intervention: Long perimenopausal period (at least 27 months)
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Prior depression
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Onset of natural menopause
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Long perimenopause
Number of subjects: 2565
Study: 2678497

Group type: EXPERIMENTAL
Intervention: Metoclopramide (15 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Droperidol (0.5 mg)
Number of subjects: 81
Study: 1098134

Group type: EXPERIMENTAL
Intervention: Buffered solution (Bamyl‐SR, AB Hässle, Sweden)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional disintegrating tablet (MagnecylR, ACO, Sweden)
Number of subjects: 7
Study: 31901246

Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (3 grams daily for 8 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 44
Study: 31238029

Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion strategy to maintain oxygen delivery index (DO2i) greater than 280 mL/min/m2
Number of subjects: 19410

Group type: COMPARATOR
Intervention: Below the optimal DO2i threshold of 270 mL/min/m2
Number of subjects: 19410
Study: 28619302

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formulas
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 117
Study: 25208904

Group type: EXPERIMENTAL
Intervention: Padma® 28 (Tibetan herbal mixture)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80